

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
06 February 2025 (06.02.2025)



(10) International Publication Number
WO 2025/029683 A1

(51) International Patent Classification:

A61K 31/395 (2006.01) A61K 31/47 (2006.01)
A61K 31/505 (2006.01) A61K 31/33 (2006.01)

(21) International Application Number:

PCT/US2024/039889

(22) International Filing Date:

26 July 2024 (26.07.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/516,375 28 July 2023 (28.07.2023) US

(71) Applicant: **COGENT BIOSCIENCES, INC.** [US/US];
275 Wyman Street, 3rd Floor, Waltham, Massachusetts
02451 (US).

(72) Inventors: **CHATTERJEE, Payal**; c/o Cogent Biosciences, 4840 Pearl E Circle, Suite 100, Boulder, Colorado 80301 (US). **CHICARELLI, Mark J.**; c/o Cogent Biosciences, 4840 Pearl E Circle, Suite 100, Boulder, Colorado 80301 (US). **CONNER, Michael L.**; c/o Cogent Biosciences, 4840 Pearl E Circle, Suite 100, Boulder, Colorado 80301 (US). **FISCHER, John**; c/o Cogent Biosciences, 4840 Pearl E Circle, Suite 100, Boulder, Colorado 80301 (US). **FULTON, Jennifer**; c/o Cogent Biosciences, 4840 Pearl E Circle, Suite 100, Boulder, Colorado 80301 (US). **JALLURI, Ravi Kumar**; c/o Cogent Biosciences, 4840 Pearl E Circle, Suite 100, Boulder, Colorado 80301 (US). **KNOX, Hailey J.**; c/o Cogent Biosciences, 4840 Pearl E Circle, Suite 100, Boulder, Colorado 80301 (US). **KUMAR, Vijay**; c/o Cogent Biosciences, 4840 Pearl E Circle, Suite 100, Boulder, Colorado 80301 (US). **NEWHOUSE, Bradley J.**; c/o Cogent Biosciences, 4840 Pearl E Circle, Suite 100, Boulder, Colorado 80301 (US). **RODRIGUEZ, Martha E.**; c/o Cogent Biosciences, 4840 Pearl E Circle, Suite 100, Boulder, Colorado 80301 (US). **SALITURO, Leah J.**; c/o Cogent Biosciences, 4840 Pearl E Circle, Suite 100, Boulder, Colorado 80301 (US). **SMITH, Aaron C.**; c/o Cogent Biosciences, 4840 Pearl E Circle, Suite 100, Boulder, Colorado 80301 (US). **STUNKARD, Lee M.**; c/o Cogent Biosciences, 4840 Pearl E Circle, Suite 100, Boul-


der, Colorado 80301 (US). **ZHOU, Yeyun**; c/o Cogent Biosciences, 4840 Pearl E Circle, Suite 100, Boulder, Colorado 80301 (US). **CARLSON, Paul R.**; c/o Cogent Biosciences, 4840 Pearl E Circle, Suite 100, Boulder, Colorado 80301 (US). **NIMAN, Scott W.**; c/o Cogent Biosciences, 4840 Pearl E Circle, Suite 100, Boulder, Colorado 80301 (US). **SUTTER, Patrick J.**; c/o Cogent Biosciences, 4840 Pearl E Circle, Suite 100, Boulder, Colorado 80301 (US). **TRUJILLO, John I.**; c/o Cogent Biosciences, 4840 Pearl E Circle, Suite 100, Boulder, Colorado 80301 (US). **VINE, Logan E.**; c/o Cogent Biosciences, 4840 Pearl E Circle, Suite 100, Boulder, Colorado 80301 (US). **VENTEICHER, Brooklynn**; c/o Cogent Biosciences, 4840 Pearl E Circle, Suite 100, Boulder, Colorado 80301 (US).

(74) Agent: **SIEKMAN, Michael** et al.; Goodwin Procter LLP, 100 Northern Avenue, Boston, Massachusetts 02210 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: PI3K INHIBITORS



(I)

(57) Abstract: A compound having the following structure of Formula (I): (I) or a stereoisomer of the compound, tautomer of the compound, pharmaceutically acceptable salt thereof, wherein R¹, R², R³, R⁴, R⁵, R⁶, A, X, Z, and Y are as defined herein. Pharmaceutical composition comprising the compounds, and their use in methods of treating diseases are also described.

[Continued on next page]

WO 2025/029683 A1

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*